Press Release


Quantoom Biosciences Launches Ntensify™ mano: A Groundbreaking kit for Rapid and Scalable mRNA Production

Nivelles, Belgium – Wednesday, March 13, 2024

Quantoom Biosciences S.A. (“Quantoom”), a subsidiary of Univercells S.A., proudly announces the extension of the Ntensify™ product line with the launch of Ntensify™ mano, an mRNA kit containing reagent mixes for mRNA production and purification in the research context. The all-in-one kit is a cost-effective solution for mRNA production.  It combines convenience, efficiency, and control. By providing optimized components for both IVT and downstream purification, Ntensify™ mano ensures high-quality results while reducing variability and saving time. The mano is based on Quantoom's existing technology but eliminates the need to invest in equipment and enables manual small-scale research production of mRNA in less than three hours.

The Ntensify™ mano kit is based on the highly successful Ntensify™ process. The effectiveness of the NtensifyTM process has already been demonstrated in larger-scale production equipment for both clinical trials and commercial production of mRNA globally. This construct-agnostic process integrates an optimized one-pot in vitro transcription with co-transcriptional capping and a redesigned single-step purification to minimize mRNA losses and increase the availability of drug-substance mRNA. The Ntensify™ process is the result of an advanced Design of Experiments (DoE) and has been continually refined over the past four years.

The Ntensify™ process has been designed to operate at different scales. Starting with the Ntensify™ mano kit, scientists can produce mRNA for research purposes without needing any specialized equipment. The same process can be seamlessly scaled up to produce small-scale quantities for pre-clinical application on the Ntensify™ mini platform. Mid-scale quantities for clinical trials require the Ntensify™ midi while large-scale commercial production can be carried out on the Ntensify™ maxi. By designing and using proprietary disposables, this range of equipment removes the need for comparability studies beyond 20mL, facilitating rapid scale-up required in pandemic contexts such as during the last COVID-19 outbreak. Quantoom Biosciences remains at the forefront of enabling its partners to achieve cost-effective, low-footprint, high-quality, and low-impurity RNA production.

José Castillo, CEO of Quantoom Biosciences and CTO of Univercells, expresses his enthusiasm: “I am thrilled about expanding our product range with the Ntensify mano. It offers an invaluable solution for researchers needing efficient mRNA production on a smaller scale and at speed. I am pleased that they will benefit from our extensive expertise in such a compact kit.

Download the press release as a pdf:

  • English

Contact Us

Please complete the form below for any commercial, partnering, media, press, or general inquiries.

If you need to contact our customer service team, please click on the button below.